VIDEO: Prostate cancer screening tool shows promise
In this video Sandeep Gurram, MD, a urologic oncologist at the National Cancer Institute in Bethesda, Maryland, discusses a study on the novel diagnostic tool, the miR Sentinel PCC4 Test, presented at the American Urological Association's annual meeting.
The study, which found that the test was an accurate noninvasive way to screen for prostate cancer, with a negative predictive value of 96%.
"The original assessment shows very positive results in that there is a 98% sensitivity and a 96% specificity, and we are distinguishing between clinically insignificant disease in Gleason grade group 1 or lower and clinically significant disease," Gurram said.
Collapse
Klotz L, et al. Abstract LBA02-09. Presented at: AUA Annual Meeting; Sept. 10-12, 2021 (virtual meeting).
Read more about